查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1986435

藥物釋放型支架市場報告：按塗層、藥物、支架平台、代數、應用、最終用戶和地區分類（2026-2034 年）

Drug-Eluting Stents Market Report by Coating, Drug, Stent Platform, Generation, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球藥物釋放型支架市場規模達92億美元。展望未來，預計到2034年，該市場規模將達到145億美元，2026年至2034年的複合年成長率為5.03%。心血管疾病盛行率的不斷上升是推動市場成長的主要因素。

藥物釋放型支架市場的發展趨勢：

新一代藥物的引入

新一代藥物釋放型支架採用生物素莫司和佐他莫司等先進藥物。這些支架在預防血管再阻塞療效較佳，同時副作用較少，因此適用於較廣泛的患者族群。例如，2024年5月，雅培公司宣佈在印度推出XIENCE SierraEverolimus（藥物洗脫）冠狀動脈支架系統。此支架已獲得CE認證，是XIENCE系列支架中最新一代產品之一，現已應用於冠狀動脈阻塞患者。這促進了藥物釋放型支架市場的成長。

擴大周邊動脈疾病的適應症

藥物釋放型支架不僅擴大用於冠狀動脈疾病的治療，也擴大用於周邊動脈疾病（PAD）的治療。這一趨勢反映了支架在治療心臟以外其他動脈閉塞方面的應用日益廣泛。 2024年4月，庫克醫療公司（Cook Medical Corporation）獲得一份契約，將向美國國防部（DoD）下屬醫院供應植入式醫療設備。該公司將提供藥物釋放型周邊支架「Zilver PTX」、主動脈腔內移植物「Zenith」以及其他植入式醫療設備。這將擴大藥物釋放型支架的市場佔有率。

對複雜病變的關注日益增加

藥物釋放型支架在治療複雜冠狀動脈疾病（例如分支病變和多支血管病變）方面需求量大。這些先進的支架旨在更精準地應對複雜的解剖結構挑戰。 2024年6月，Elixir Medical公司的DynamXSirolimus洗脫冠狀動脈生物適配器系統獲得了FDA的突破性醫療器材認定。這種自我調整植入旨在改善冠狀動脈直徑，恢復血流動力學，並抑制有症狀缺血性心臟疾病患者的斑塊進展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球藥物釋放型支架市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依塗料分類

  • 聚合物基塗料
  • 無聚合物塗層

第7章 市場區隔：依藥物分類

  • Sirolimus
  • 紫杉醇
  • 佐他羅莫司
  • Everolimus
  • 生物黏膜
  • 其他

第8章 市場區隔：依支架平台分類

  • 不銹鋼
  • 鈷鉻合金
  • 鉑金鉻
  • 鎳鈦諾
  • 其他

第9章 市場區隔：依世代分類

  • 第一代
  • 第二代
  • 第三代
  • 第四代

第10章 市場區隔：依應用領域分類

  • 冠狀動脈疾病
  • 周邊動脈疾病

第11章 市場區隔：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 其他

第12章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第13章 SWOT 分析

第14章：價值鏈分析

第15章：波特五力分析

第16章：價格分析

第17章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott
    • B. Braun SE
    • Biosensors International Group, Ltd.
    • Biotronik
    • Boston Scientific Corporation
    • Cook Medical
    • Lepu Medical Technology（Beijing）Co., Ltd
    • Medinol
    • Medtronic plc
    • MicroPort Scientific Corporation
    • Sino Medical Sciences Technology Inc
    • Terumo Corporation
Product Code: SR112026A4815

The global drug-eluting stents market size reached USD 9.2 Billion in 2025. Looking forward, the market is expected to reach USD 14.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.03% during 2026-2034. The increasing prevalence of cardiovascular diseases is propelling the market.

DRUG-ELUTING STENTS MARKET ANALYSIS:

  • Major Market Drivers: The increasing prevalence of irregular heart rhythms, heart failure, and heart attack disease is stimulating the market.
  • Key Market Trends: The widespread use of stents with polymer-free coatings is acting as a significant growth-inducing factor.
  • Competitive Landscape: Some of the major market companies include Abbott, B. Braun SE, Biosensors International Group, Ltd., Biotronik, Boston Scientific Corporation, Cook Medical, Lepu Medical Technology (Beijing) Co., Ltd, Medinol, Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc and Terumo Corporation, among many others.
  • Geographical Trends: North America dominates the market owing to a robust healthcare system, rising incidence of coronary artery disease, and extensive use of innovative medical technologies.
  • Challenges and Opportunities: The risk of late stent thrombosis is hampering the market. However, developing innovative stent technologies with greater biocompatibility and polymer-free coatings to increase patient safety is expected to fuel the market in the coming years.

DRUG-ELUTING STENTS MARKET TRENDS:

Implementation of Next-Generation Drugs

The next generation of drug-eluting stents uses advanced medications, such as biolimus and zotarolimus, which have higher efficacy in preventing restenosis while reducing adverse effects, making these stents more useful for a wider variety of patients. For example, in May 2024, Abbott announced the launch of XIENCE Sierra Everolimus (drug) eluting coronary stent system in India. It is a CE-marked and one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. This is leading to the drug-eluting stents market growth.

Expanded Use in Peripheral Artery Disease

Drug-eluting stents are being increasingly utilized to treat peripheral arterial disease (PAD), moving beyond coronary applications. This trend reflects stents' growing use in treating blockages in arteries beyond the heart. In April 2024, Cook Medical received a contract to supply implantable devices to hospitals run by the U.S. Department of Defense (DoD). The company would provide its Zilver PTX drug-eluting peripheral stent, Zenith aortic endograft, and other implantable devices. This is expanding the drug-eluting stents market share.

Increasing Focus on Complex Lesions

Drug-eluting stents are in high demand for treating complicated coronary lesions such as bifurcation and multi-vessel disease. These advanced stents are designed to handle complex anatomical issues with more precision. In June 2024, Elixir Medical's DynamX Sirolimus-Eluting Coronary Bioadaptor System received Breakthrough Device Designation from the FDA. This bioadaptive implant aims to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.

GLOBAL DRUG-ELUTING STENTS INDUSTRY SEGMENTATION:

Breakup by Coating:

  • Polymer Based Coating
  • Polymer Free Coating

Among these, polymer free coating holds the largest share of the drug-eluting stents market

Polymer free coating is intended to minimize inflammation and promote healing. These coatings improve medication delivery while eliminating the problems associated with polymers, resulting in better patient outcomes during cardiovascular treatments. This is elevating the drug-eluting stents market revenue.

Breakup by Drug:

  • Sirolimus
  • Paclitaxel
  • Zotarolimus
  • Everolimus
  • Biolimus
  • Others

The drug-eluting stents market overview highlights that sirolimus reduces cell development to avoid arterial narrowing, while paclitaxel inhibits cell division, resulting in better blood flow. Zotarolimus enhances healing while causing less adverse effects, and everolimus has been shown to reduce re-narrowing over time. Biolimus, a biodegradable alternative, promotes vascular recovery, providing a variety of therapy options in the market.

Breakup by Stent Platform:

  • Stainless-steel
  • Cobalt-Chromium
  • Platinum-Chromium
  • Nitinol
  • Others

Cobalt-chromium currently holds the largest drug-eluting stents market demand

Cobalt-chromium stents are well-known for their long-lasting, flexible, and biocompatible design. These stents have a sturdy construction but allow for thinner struts, which improves vessel support and reduces problems during cardiovascular treatments. This is elevating the drug-eluting stents market statistics.

Breakup by Generation:

  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • 4th Generation

The 1st generation drug-eluting stents used basic drug coatings to minimize restenosis. The 2nd generation increased safety by improving biocompatibility and using thinner struts. The 3rd generation focused on biodegradable polymers to improve healing, while the 4th generation uses polymer-free coatings to promote speedier recovery and reduce inflammation. Each generation represents advances in safety, efficacy, and patient outcomes.

Breakup by Application:

  • Coronary Artery Disease
  • Peripheral Artery Disease

Currently, coronary artery disease holds the largest share of the drug-eluting stents market recent price

The market largely focuses on coronary artery disease by releasing medications that prevent restenosis. These stents help to maintain artery patency, improve blood flow, and reduce the need for repeat treatments in patients with blocked or narrowed arteries.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Among these, hospitals currently hold the largest share of the market

Hospitals are the primary end users in this market, as these devices are commonly utilized in cardiovascular surgeries to treat coronary artery disease. These stents are used in hospitals to improve patient outcomes, lower restenosis, and reduce the need for recurrent treatments. This represents one of the drug-eluting stents market recent opportunities.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America currently dominates the drug-eluting stents market outlook

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America exhibits a clear dominance in the market. This can be attributed to the enhanced healthcare infrastructure, a high prevalence of cardiovascular illnesses, and the growing adoption of cutting-edge stent technology. The region's focus on reducing coronary artery disease promotes demand for these devices.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major drug-eluting stents market companies have also been provided. Some of the key players in the market include:

  • Abbott
  • B. Braun SE
  • Biosensors International Group, Ltd.
  • Biotronik
  • Boston Scientific Corporation
  • Cook Medical
  • Lepu Medical Technology (Beijing) Co., Ltd
  • Medinol
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Sino Medical Sciences Technology Inc
  • Terumo Corporation

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global drug-eluting stents market in 2025?

2. What is the expected growth rate of the global drug-eluting stents market during 2026-2034?

3. What are the key factors driving the global drug-eluting stents market?

4. What has been the impact of COVID-19 on the global drug-eluting stents market?

5. What is the breakup of the global drug-eluting stents market based on the coating?

6. What is the breakup of the global drug-eluting stents market based on the stent platform?

7. What is the breakup of the global drug-eluting stents market based on application?

8. What is the breakup of the global drug-eluting stents market based on the end user?

9. What are the key regions in the global drug-eluting stents market?

10. Who are the key players/companies in the global drug-eluting stents market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Drug-Eluting Stents Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Coating

  • 6.1 Polymer Based Coating
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymer Free Coating
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug

  • 7.1 Sirolimus
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Paclitaxel
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Zotarolimus
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Everolimus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Biolimus
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Stent Platform

  • 8.1 Stainless-steel
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cobalt-Chromium
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Platinum-Chromium
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Nitinol
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Generation

  • 9.1 1st Generation
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 2nd Generation
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 3rd Generation
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 4th Generation
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Application

  • 10.1 Coronary Artery Disease
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Peripheral Artery Disease
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by End User

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Ambulatory Surgical Centers
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Others
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 B. Braun SE
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 SWOT Analysis
    • 17.3.3 Biosensors International Group, Ltd.
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
    • 17.3.4 Biotronik
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 SWOT Analysis
    • 17.3.5 Boston Scientific Corporation
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 Cook Medical
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 SWOT Analysis
    • 17.3.7 Lepu Medical Technology (Beijing) Co., Ltd
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
    • 17.3.8 Medinol
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Medtronic plc
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 MicroPort Scientific Corporation
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
    • 17.3.11 Sino Medical Sciences Technology Inc
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
    • 17.3.12 Terumo Corporation
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Drug-Eluting Stents Market: Major Drivers and Challenges
  • Figure 2: Global: Drug-Eluting Stents Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Drug-Eluting Stents Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Drug-Eluting Stents Market: Breakup by Coating (in %), 2025
  • Figure 5: Global: Drug-Eluting Stents Market: Breakup by Drug (in %), 2025
  • Figure 6: Global: Drug-Eluting Stents Market: Breakup by Stent Platform (in %), 2025
  • Figure 7: Global: Drug-Eluting Stents Market: Breakup by Generation (in %), 2025
  • Figure 8: Global: Drug-Eluting Stents Market: Breakup by Application (in %), 2025
  • Figure 9: Global: Drug-Eluting Stents Market: Breakup by End User (in %), 2025
  • Figure 10: Global: Drug-Eluting Stents Market: Breakup by Region (in %), 2025
  • Figure 11: Global: Drug-Eluting Stents (Polymer Based Coating) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Drug-Eluting Stents (Polymer Based Coating) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Drug-Eluting Stents (Polymer Free Coating) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Drug-Eluting Stents (Polymer Free Coating) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Drug-Eluting Stents (Sirolimus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Drug-Eluting Stents (Sirolimus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Drug-Eluting Stents (Paclitaxel) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Drug-Eluting Stents (Paclitaxel) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Drug-Eluting Stents (Zotarolimus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Drug-Eluting Stents (Zotarolimus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Drug-Eluting Stents (Everolimus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Drug-Eluting Stents (Everolimus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Drug-Eluting Stents (Biolimus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Drug-Eluting Stents (Biolimus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Drug-Eluting Stents (Other Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Drug-Eluting Stents (Other Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Drug-Eluting Stents (Stainless-steel) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Drug-Eluting Stents (Stainless-steel) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Drug-Eluting Stents (Cobalt-Chromium) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Drug-Eluting Stents (Cobalt-Chromium) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Drug-Eluting Stents (Platinum-Chromium) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Drug-Eluting Stents (Platinum-Chromium) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Drug-Eluting Stents (Nitinol) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Drug-Eluting Stents (Nitinol) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Drug-Eluting Stents (Other Stent Platforms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Drug-Eluting Stents (Other Stent Platforms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Drug-Eluting Stents (1st Generation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Drug-Eluting Stents (1st Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Drug-Eluting Stents (2nd Generation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Drug-Eluting Stents (2nd Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Drug-Eluting Stents (3rd Generation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Drug-Eluting Stents (3rd Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Drug-Eluting Stents (4th Generation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Drug-Eluting Stents (4th Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Drug-Eluting Stents (Coronary Artery Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Drug-Eluting Stents (Coronary Artery Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Drug-Eluting Stents (Peripheral Artery Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Global: Drug-Eluting Stents (Peripheral Artery Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Global: Drug-Eluting Stents (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Global: Drug-Eluting Stents (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Global: Drug-Eluting Stents (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Global: Drug-Eluting Stents (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Global: Drug-Eluting Stents (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Global: Drug-Eluting Stents (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: North America: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: North America: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United States: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United States: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Canada: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Canada: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Asia-Pacific: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Asia-Pacific: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: China: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: China: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Japan: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Japan: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: India: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: India: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: South Korea: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: South Korea: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Australia: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Australia: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Indonesia: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Indonesia: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Europe: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Europe: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Germany: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Germany: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: France: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: France: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: United Kingdom: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: United Kingdom: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Italy: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Italy: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Spain: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Spain: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Russia: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Russia: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Others: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Others: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Latin America: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Latin America: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Brazil: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 96: Brazil: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 97: Mexico: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 98: Mexico: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 99: Others: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 100: Others: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 101: Middle East and Africa: Drug-Eluting Stents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 102: Middle East and Africa: Drug-Eluting Stents Market: Breakup by Country (in %), 2025
  • Figure 103: Middle East and Africa: Drug-Eluting Stents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 104: Global: Drug-Eluting Stents Industry: SWOT Analysis
  • Figure 105: Global: Drug-Eluting Stents Industry: Value Chain Analysis
  • Figure 106: Global: Drug-Eluting Stents Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Drug-Eluting Stents Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Drug-Eluting Stents Market Forecast: Breakup by Coating (in Million USD), 2026-2034
  • Table 3: Global: Drug-Eluting Stents Market Forecast: Breakup by Drug (in Million USD), 2026-2034
  • Table 4: Global: Drug-Eluting Stents Market Forecast: Breakup by Stent Platform (in Million USD), 2026-2034
  • Table 5: Global: Drug-Eluting Stents Market Forecast: Breakup by Generation (in Million USD), 2026-2034
  • Table 6: Global: Drug-Eluting Stents Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 7: Global: Drug-Eluting Stents Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 8: Global: Drug-Eluting Stents Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 9: Global: Drug-Eluting Stents Market: Competitive Structure
  • Table 10: Global: Drug-Eluting Stents Market: Key Players